1584 related articles for article (PubMed ID: 11426523)
1. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
2. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
3. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Pedersen-Bjergaard J; Pedersen M; Myhre J; Geisler C
Leukemia; 1997 Oct; 11(10):1654-60. PubMed ID: 9324285
[TBL] [Abstract][Full Text] [Related]
4. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Jang GD; Kim SW; Suh CW; Kim EK; Bahng HS; Jeong YH; Park IG; Kim WK; Kim SH; Suh EJ; Park CJ; Ji HS; Lee JS
J Korean Med Sci; 2002 Aug; 17(4):555-9. PubMed ID: 12172056
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP
J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
[TBL] [Abstract][Full Text] [Related]
7. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Krishnan A; Bhatia S; Slovak ML; Arber DA; Niland JC; Nademanee A; Fung H; Bhatia R; Kashyap A; Molina A; O'Donnell MR; Parker PA; Sniecinski I; Snyder DS; Spielberger R; Stein A; Forman SJ
Blood; 2000 Mar; 95(5):1588-93. PubMed ID: 10688812
[TBL] [Abstract][Full Text] [Related]
8. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
9. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
10. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
Horning SJ; Chao NJ; Negrin RS; Hoppe RT; Kwak LW; Long GD; Stallbaum B; O'Connor P; Blume KG
Ann Oncol; 1991 Jan; 2 Suppl 1():47-50. PubMed ID: 2043498
[TBL] [Abstract][Full Text] [Related]
11. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
[TBL] [Abstract][Full Text] [Related]
12. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
Sobecks RM; Le Beau MM; Anastasi J; Williams SF
Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
[TBL] [Abstract][Full Text] [Related]
16. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Alvarnas JC; Negrin RS; Horning SJ; Hu WW; Long GD; Schriber JR; Stockerl-Goldstein K; Tierney K; Wong R; Blume KG; Chao NJ
Biol Blood Marrow Transplant; 2000; 6(3A):352-8. PubMed ID: 10905773
[TBL] [Abstract][Full Text] [Related]
17. Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Robertson MJ; Abonour R; Hromas R; Nelson RP; Fineberg NS; Cornetta K
Leuk Lymphoma; 2005 Oct; 46(10):1477-87. PubMed ID: 16194894
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Berglund A; Enblad G; Carlson K; Glimelius B; Hagberg H
Eur J Haematol; 2000 Jul; 65(1):17-22. PubMed ID: 10914935
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
